These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

471 related items for PubMed ID: 18954982

  • 1. Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
    Vendeville S, Nilsson M, de Kock H, Lin TI, Antonov D, Classon B, Ayesa S, Ivanov V, Johansson PO, Kahnberg P, Eneroth A, Wikstrom K, Vrang L, Edlund M, Lindström S, Van de Vreken W, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Van Dooren M, Kindermans N, Surleraux D, Wigerinck P, Rosenquist A, Samuelsson B, Simmen K, Raboisson P.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6189-93. PubMed ID: 18954982
    [Abstract] [Full Text] [Related]

  • 2. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 3. Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.
    Raboisson P, Lin TI, Kock Hd, Vendeville S, Vreken WV, McGowan D, Tahri A, Hu L, Lenz O, Delouvroy F, Surleraux D, Wigerinck P, Nilsson M, Rosenquist S, Samuelsson B, Simmen K.
    Bioorg Med Chem Lett; 2008 Sep 15; 18(18):5095-100. PubMed ID: 18722116
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
    Llinàs-Brunet M, Bailey MD, Bolger G, Brochu C, Faucher AM, Ferland JM, Garneau M, Ghiro E, Gorys V, Grand-Maître C, Halmos T, Lapeyre-Paquette N, Liard F, Poirier M, Rhéaume M, Tsantrizos YS, Lamarre D.
    J Med Chem; 2004 Mar 25; 47(7):1605-8. PubMed ID: 15027850
    [Abstract] [Full Text] [Related]

  • 5. Potent and selective small molecule NS3 serine protease inhibitors of Hepatitis C virus with dichlorocyclopropylproline as P2 residue.
    Chen KX, Vibulbhan B, Yang W, Cheng KC, Liu R, Pichardo J, Butkiewicz N, Njoroge FG.
    Bioorg Med Chem; 2008 Feb 15; 16(4):1874-83. PubMed ID: 18032054
    [Abstract] [Full Text] [Related]

  • 6. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
    Chen KX, Nair L, Vibulbhan B, Yang W, Arasappan A, Bogen SL, Venkatraman S, Bennett F, Pan W, Blackman ML, Padilla AI, Prongay A, Cheng KC, Tong X, Shih NY, Njoroge FG.
    J Med Chem; 2009 Mar 12; 52(5):1370-9. PubMed ID: 19196021
    [Abstract] [Full Text] [Related]

  • 7. Novel potent inhibitors of hepatitis C virus (HCV) NS3 protease with cyclic sulfonyl P3 cappings.
    Chen KX, Vibulbhan B, Yang W, Nair LG, Tong X, Cheng KC, Njoroge FG.
    Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1105-9. PubMed ID: 19168351
    [Abstract] [Full Text] [Related]

  • 8. Potent triazolyl-proline-based inhibitors of HCV NS3 protease.
    Naud J, Lemke C, Goudreau N, Beaulieu E, White PD, Llinàs-Brunet M, Forgione P.
    Bioorg Med Chem Lett; 2008 Jun 01; 18(11):3400-4. PubMed ID: 18448339
    [Abstract] [Full Text] [Related]

  • 9. Discovery of novel urea-based hepatitis C protease inhibitors with high potency against protease-inhibitor-resistant mutants.
    Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A, Li X, Zhang S, Zhang YK, Liu Y, Ding CZ, Zhou Y, Plattner JJ, Baker SJ, Bu W, Liu L.
    J Med Chem; 2012 Apr 12; 55(7):3021-6. PubMed ID: 22471376
    [Abstract] [Full Text] [Related]

  • 10. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
    Johansson PO, Bäck M, Kvarnström I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5136-51. PubMed ID: 16675222
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
    Li X, Liu Y, Zhang YK, Plattner JJ, Baker SJ, Bu W, Liu L, Zhou Y, Ding CZ, Zhang S, Kazmierski WM, Hamatake R, Duan M, Wright LL, Smith GK, Jarvest RL, Ji JJ, Cooper JP, Tallant MD, Crosby RM, Creech K, Wang A.
    Bioorg Med Chem Lett; 2012 Dec 15; 22(24):7351-6. PubMed ID: 23142614
    [Abstract] [Full Text] [Related]

  • 12. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
    Bogen SL, Arasappan A, Velazquez F, Blackman M, Huelgas R, Pan W, Siegel E, Nair LG, Venkatraman S, Guo Z, Doll R, Shih NY, Njoroge FG.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1854-65. PubMed ID: 20149666
    [Abstract] [Full Text] [Related]

  • 13. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS.
    Biopolymers; 2004 Mar 01; 76(4):309-23. PubMed ID: 15386268
    [Abstract] [Full Text] [Related]

  • 14. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
    Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V.
    J Med Chem; 2007 May 17; 50(10):2310-8. PubMed ID: 17444623
    [Abstract] [Full Text] [Related]

  • 15. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S, Robertson K, Hernando JI, DiMuzio J, Summa V.
    Bioorg Med Chem Lett; 2009 Apr 15; 19(8):2295-8. PubMed ID: 19285390
    [Abstract] [Full Text] [Related]

  • 16. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
    Liverton NJ, Holloway MK, McCauley JA, Rudd MT, Butcher JW, Carroll SS, DiMuzio J, Fandozzi C, Gilbert KF, Mao SS, McIntyre CJ, Nguyen KT, Romano JJ, Stahlhut M, Wan BL, Olsen DB, Vacca JP.
    J Am Chem Soc; 2008 Apr 09; 130(14):4607-9. PubMed ID: 18338894
    [Abstract] [Full Text] [Related]

  • 17. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
    Njoroge FG, Chen KX, Shih NY, Piwinski JJ.
    Acc Chem Res; 2008 Jan 09; 41(1):50-9. PubMed ID: 18193821
    [Abstract] [Full Text] [Related]

  • 18. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
    Bogen SL, Pan W, Ruan S, Nair LG, Arasappan A, Bennett F, Chen KX, Jao E, Venkatraman S, Vibulbhan B, Liu R, Cheng KC, Guo Z, Tong X, Saksena AK, Girijavallabhan V, Njoroge FG.
    J Med Chem; 2009 Jun 25; 52(12):3679-88. PubMed ID: 19456105
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.